Johnson & Johnson $JNJ delivered robust first-quarter results that exceeded Wall Street expectations, setting a positive tone for the company's overall financial performance. The reported revenue reached USD 21.89 billion, representing a 2.4% increase compared to the same quarter last year, surpassing forecasts of USD 21.56 billion. Adjusted earnings per share climbed to USD 2.77, up 2.2% year-over-year and outperforming analysts’ projections of USD 2.59.

Johnson & Johnson, a global leader in pharmaceuticals and medical devices, recently announced an ambitious plan to invest over $55 billion in expanding its manufacturing capacity and research infrastructure in the United States over the next four years. This strategic move represents a 25% increase in investments compared to the previous four-year period, reflecting the company's strong commitment to bolstering its production and research capabilities on American soil.